Видео ютуба по тегу Neoadj Chemo

NIAGARA - New Standard for Muscle Invasive Bladder Cancer with Neoadj Chemo & Periop Durvalumab
NIAGARA - New Standard for Muscle Invasive Bladder Cancer with Neoadj Chemo & Periop Durvalumab
#ESMO22 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma:SWOG S1801
#ESMO22 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma:SWOG S1801
Dilemmas in Mgmt of Ca Prostate-NeoAdj Chemo, ARTIs, Positive margin, BCR, LN Mgmt (UROONCOCON 2024)
Dilemmas in Mgmt of Ca Prostate-NeoAdj Chemo, ARTIs, Positive margin, BCR, LN Mgmt (UROONCOCON 2024)
CheckMate-77T (Periop Nivolumab) vs. CheckMate-816 (Neoadj Nivolumab) - WCLC 2024 Highlights
CheckMate-77T (Periop Nivolumab) vs. CheckMate-816 (Neoadj Nivolumab) - WCLC 2024 Highlights
Breast Cancer Treatment Before Surgery: What You Need to Know About Neoadjuvant Therapy
Breast Cancer Treatment Before Surgery: What You Need to Know About Neoadjuvant Therapy
ESMO 2020 Highlights on neoadjuvant ICI in early TNBC: The IMpassion031 study
ESMO 2020 Highlights on neoadjuvant ICI in early TNBC: The IMpassion031 study
ADCs for the treatment of bladder cancer in the neoadjuvant setting
ADCs for the treatment of bladder cancer in the neoadjuvant setting
HER2-позитивный рак молочной железы на ранней стадии (неоадъювантная/адъювантная терапия): Симпоз...
HER2-позитивный рак молочной железы на ранней стадии (неоадъювантная/адъювантная терапия): Симпоз...
#UromigosLive24 Periop UC Panel Pt 3: Neoadj. ADC/PD-L1 Combos, TAR-200, Bladder-Sparing Approaches
#UromigosLive24 Periop UC Panel Pt 3: Neoadj. ADC/PD-L1 Combos, TAR-200, Bladder-Sparing Approaches
Debate-Definitive chemorad vs Neoadj chemorad followed by sx in midthorax squamous cell ca esophagus
Debate-Definitive chemorad vs Neoadj chemorad followed by sx in midthorax squamous cell ca esophagus
Neoadjuvant vs. Adjuvant vs. None – “Perioperative Therapy”
Neoadjuvant vs. Adjuvant vs. None – “Perioperative Therapy”
Adjuvant and neoadjuvant chemo-IO for UK patients with NSCLC
Adjuvant and neoadjuvant chemo-IO for UK patients with NSCLC
Breast Cancer Research at ESMO 20: Elizabeth Ann Mittendorf, MD, PhD
Breast Cancer Research at ESMO 20: Elizabeth Ann Mittendorf, MD, PhD
Ключевые выводы исследований рака легких на конференции ASCO 2025
Ключевые выводы исследований рака легких на конференции ASCO 2025
ESMO 2020 Expert Video report on atezolizumab in upfront treatment of TNBC
ESMO 2020 Expert Video report on atezolizumab in upfront treatment of TNBC
GI Cancer ASCO 2023 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Muhammad Shaalan Beg
GI Cancer ASCO 2023 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Muhammad Shaalan Beg
#ESMO22 Highlights on first-line atezolizumab in NSCLC not eligible for platinum: The IPSOS study
#ESMO22 Highlights on first-line atezolizumab in NSCLC not eligible for platinum: The IPSOS study
Updates in melanoma at ESMO 2022
Updates in melanoma at ESMO 2022
Neoadjuvant Therapy for Melanoma
Neoadjuvant Therapy for Melanoma
Tumor characteristics of patients with recurrence after neoadjuvant ipi + nivo in melanoma
Tumor characteristics of patients with recurrence after neoadjuvant ipi + nivo in melanoma